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Two four-treatment crossover bioavailability studies were performed in panels of 12 adult male 
volunteers with eight different commercial prednisone tablets. Plasma samples from the first study 
were assayed by radioimmunoassay for both prednisone and prednisolone. Plasma samples from 
the second study were assayed for prednisolone only. Statistical analyses of the data showed 
significant differences in the rate of appearance of prednisolone in plasma, but not in the amount 
converted to prednisolone. Some observations are made on the relationships between prednisone 
and prednisolone concentrations in plasma following oral ~lministration of prednisone. 
KEY W O R D S :  prednisone bioavailability; elimination half-lives of prednisone and predni- 
solone; prednisone and prednisolone plasma levels following prednisone. 
INTRODUCTION 
With the development of radioimmunoassays for prednisone (1) and its 
metabolite, prednisolone (2), it is now possible to measure the plasma levels 
of these steroids following the oral administration of a single, low dose of 
prednisone. The early observations, of Campagna et al. (3) and Levy et al. (4) 
demonstrated a potential bioavailability problem with prednisone tablets 
which only recently could begin to be assessed. Two earlier papers (5,6) 
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reported data on some prednisone tablets. One of these (6) reported results 
of our first prednisone study. 
It is well documented that prednisone is metabolized to prednisolone 
(7-9), which is assumed to be its active form. However, in most of these 
studies the metabolites of prednisolone have been isolated only from urine, 
or plasma levels of prednisolone have been measured following high doses 
of prednisone. In only one unpublished study of DiSanto et al. has the 
determination of both prednisone and prednisolone in plasma been under- 
taken. 
This article reports the results of two four-treatment crossover studies 
with commercially available prednisone tablets. In the second prednisone 
study both prednisone and prednisolone plasma levels were measured, while 
in the third prednisone study only prednisolone was measured in plasma. 
All tablets utilized in the studies were purchased on the open market by the 
Food and Drug Administration. 
EXPERIMENTAL 
In Vitro Studies 
Dissolution testing was performed in the laboratories of the Food and 
Drug Administration according to the specifications of the USP XVIII. 
Results of dissolution rate tests on the same tablets by another method will 
be reported in a subsequent publication. 
Subjects 
Twelve adult male volunteers between the ages of 21 and 32 years, 
weighing between 60.3 and 82.6 kg and in good health, were selected for each 
study. Six of the subjects participated in both studies. Each subject received 
a medical history, physical examination, and blood and urine analysis 
including plasma 17-OHCS. 
All subjects selected received no barbiturates or other enzyme-inducing 
agents for a period of 30 days preceding the study until its completion. They 
received no other medication or alcoholic beverages for a period beginning 
7 days preceding the study until completion of the study. The subjects were 
assigned numbers which were ordered according to increasing body weight. 
Study Conditions 
Subjects fasted overnight (from 10 P.M.) until 4 hr after administration 
of each dose of prednisone. On the mornings when medication was ad- 
ministered, each subject drank 240 ml of water within the first hour after 
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arising. F r o m  4 hr after dosing with prednisone,  food and  beverage  were 
taken ad libitum. 
Blood Sampling 
Fifty milliliters of  whole b lood  was taken  f rom a fo rea rm vein just  
before dosing with prednisone at 0 time, and 12 ml (Study 2) or 10 ml (Study 3) 
of  whole b lood  was taken  at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hr after dosing 
with prednisone.  The b lood  samples  were d rawn into Vacuta iner  tubes 
containing hepar in  as the ant icoagulant .  Each sample  of  b lood  was centri- 
fuged as soon as possible after collection and the p lasma  was placed in one 
vial, s toppered,  and labeled immediate ly .  The  p lasma  samples  were then 
quick frozen, and stored in the frozen state until just  pr ior  to assay. 
Treatments  and Schedules 
At 11 P.M. on the day before each t rea tment  period,  each subject t ook  
1.0 mg  of dexamethasone  orally to suppress  the endogenous  secretion of 
cortisol. At 8 hr after prednisone  adminis t ra t ion ,  each subject took  0.5 mg  
of dexamethasone  orally to main ta in  the suppression.  
On  each phase  of Study 2, each subject ingested 10 mg  of prednisone  as 
two 5-mg tablets  N, D, U, or R. 4 The  tablets  were taken  in the morn ing  
(about  8 A.M.) with 180 ml of water.  T rea tmen t s  were separa ted  by a 1-week 
period.  
4Tablet N was prednisone, 5 mg (Nysco Laboratories), lot No. 49571 ; tablet D was prednisone, 
5 mg (Danbury Pharmacal, Inc.), lot No. 4539; tablet U was Deltasone, 5 mg (Upjohn Co.), 
lot No. 786AEFI; tablet R was prednisone, 5 mg (Rexall Drug Co.), lot No. E 11499. 
Table I. Treatment Schedules 
Time period 
Study Subject Group Week I Week II Week III Week IV 
1,2, 3 I N D R U 
4, 5,6 II D U N R 
7, 8, 9 III U R D N 
10, 11, 12 IV R N U D 
1,2, 3 I L B S Mc 
4, 5, 6 II B Mc L S 
7, 8, 9 III Mc S B L 
10, 11, 12 IV S L Mc B 
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The same protocol was repeated during Study 3 when each subject 
ingested 10 mg of prednisone as two 5-mg tablets of L, B, Me, or S. s 
The treatment schedules are shown in Table I. Studies 2 and 3 were 
separated by a period of approximately 6 months. 
Assay of  Plasma Samples 
The plasma concentrations of prednisone and its metabolite, predni- 
solone, were determined independently in each plasma sample from Study 2. 
The plasma concentration of prednisolone was determined in each plasma 
sample from Study 3. Each compound was measured by a radioimmunoassay 
procedure. The radioimmunoassay procedure for prednisolone has been 
given previously (10). 
The procedure of Colburn (1) for the radioimmunoassay of prednisone 
was modified as follows: One milliliter of diluted plasma was incubated at 
37~ for 10 min with 10 #1 (2700 cpm) of ethanolic 3H-prednisone solution 
and 20 pl of antiserum. This incubation was followed by a second incubation 
at 0~ for i0 min. Two milliliters of a cold, saturated aqueous solution of 
ammonium sulfate was added to each sample and the solutions were mixed 
thoroughly. Each sample was centrifuged for 20 min at 2000 rpm. Following 
centrifugation, 1 ml of supernate was transferred to a scintillation vial 
containing 10 ml of Unogel and the radioactivity was counted for 10 min. 
Binding curves were prepared using 0, 0.05, 0.25, 0.505, 1.01, and 2.02 ng 
of prednisone. Because of the high sentivity of this procedure, plasma 
samples had to be diluted with phosphate-buffered saline (pH 7.4) to be 
within the range of the assay. A 1 : 100 dilution was commonly used, but a 
1:20 dilution was required for some samples. Binding curves were prepared 
for dilutions which were similar to those of the samples to be assayed, using 
each subject's "zero hour"  plasma. 
All binding curves were fitted essentially perfectly to a triexponential 
equation with the N O N L I N  program using an IBM 360/67 computer. The 
concentration of prednisone in the experimental samples was then deter- 
mined by an iterative program using a Hewlett-Packard 9100A calculator. 
This procedure is more accurate than reading the concentration by sight 
from a standard curve. 
RESULTS AND DISCUSSIONS 
In Vitro Studies 
The results of the USP dissolution testing of the tablets studied as 
reported by the Food and Drug Administration are summarized in Table II. 
5Tablet L was prednisone, 5 mg (Lemmon Pharmacal), lot No. 1382; tablet B was prednisone, 
5mg (Barr Laboratories), lot No. 4126111; tablet Mc was prednisone, 5mg (McKesson 
Laboratories), lot No. 3K668 ; tablet S was Meticorten, 5 mg (Schering Corp.), lot No. 2ABB- 
804. 
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Table II. Summary of Results of USP Dissolution Test Performed 
on Prednisone Tablets 
Percent dissolved in 20 rain 
Tablet Average st> Range 
N 47.5 4.09 40.7-55.2 
D 4.84 1.65 1.6-8.2 
U 103 1.61 102-105 
R 40.6 13.9 18.6-61.2 
L 39.0 7.94 28.4-60.8 
B 54.2 1.89 50.9-56.7 
Mc 34.7 23.5 12.7-89.8 
S 112 2.96 108-118 
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The USP dissolution test requires that at least 60 % of the labeled amount of 
prednisone in a tablet be dissolved in 20 rain in the USP apparatus. Of the 
eight commercial products tested, only tablets U and S met this requirement. 
Tablet D was the slowest-dissolving tablet, with an average of 4.84% of 
label dissolved in 20min. The remaining tablets were of intermediate 
dissolution rates, with average percent of label dissolved in 20 rain ranging 
between 34.7% and 54.2%. The Food and Drug Administration has 
reported to us that there were problems in reproducing results from one 
laboratory to another with these tablets using the USP dissolution test. 
Assay Methods 
The cross-reactivity of the prednisone and prednisolone antiserum with 
various endogenous steroids has been reported (1,2). The major interferences 
that could be anticipated are the reactions of cortisone with the prednisone 
antiserum and of cortisol with the prednisolone antiserum. In order to 
maintain the specificity of the assay technique, dexamethasone was ad- 
ministered to suppress the secretion of endogenous cortisol (9,11). Dex- 
amethasone does not bind to either the prednisone or the prednisolone 
antiserum. 
Plasma Levels of Prednisone in Study 2 
Table III summarizes the results of Study 2 obtained by measurement 
of plasma levels of prednisone, and the statistical analyses of these data. 
Analysis of variance for crossover design (ANOVA) of plasma concentra- 
tions indicated highly significant treatment differences among average 
plasma concentrations of prednisone at all sampling times except 24 hr. 
Dunnett's multiple comparison procedure (12) was used to identify signifi- 
cant differences between pairs of tablet gverages. Tablet U was selected as 
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Again significant differences between average plasma concentrations were 
seen following tablet U compared to each of the other tablets up to approx- 
imately 8 hr after administration. 
Average area (both 0-12 and 0-24 hr), average peak plasma concentra- 
tion, and average time to reach peak plasma concentration demonstrated 
significant differences among tablets. The differences between average areas 
and average peak plasma concentrations remained significant when tablet U 
was compared with tablets N and R, but not when compared with tablet D. 
The difference between average time to reach peak plasma concentration was 
not significant when tablet U was compared with tablet N, but was signifi- 
cant in the cases when tablet U was compared with tablet D or R. 
The coefficients of variation of the averages given in Table III are given 
in Table X. 
Plasma Levels of Prednisolone in Study 2 
Table IV summarizes the results obtained when plasma concentrations 
of prednisolone were measured in Study 2 and the table also gives results of 
statistical analyses of these data by ANOVA. Significant differences among 
tablet average plasma concentrations at each sampling time, except 2 and 3 hr, 
were found. The differences between tablet averages were significant only 
when tablet U was compared with tablet D. There were no significant dif- 
ferences between tablet average plasma concentrations when tablet U was 
compared with either tablet N or R. 
There were significant differences among average treatment areas 
0-24 hr and among average peak plasma concentrations, but not among 
average areas 0-12 hr. Average time to reach peak plasma concentration 
demonstrated a significant difference when tablet U was compared with 
tablet D. 
The coefficients of variation of the averages shown in Table IV are 
given in Table X. 
Relationship Between Prednisone and Prednisolone Plasma Levels in Study 2 
Since prednisone is assumed to be biologically inactive, and predni- 
nosolone is assumed to be the biologically active steroid, the proportions of 
these two steroids in plasma are of interest. Tablet average plasma prednisone 
and prednisolone levels obtained in Study 2 are plotted in Fig. 1. Table V 
presents the average percentages 
concentration of prednisone 
x 100 
concentration of prednisone + concentration of prednisolone 
by tablet at each sampling time. Two observations can be made from these 
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Fig. 1. Average plasma concentrations of prednisone (0)  and prednisolone (m) from 
Study 2. 
data. First, this percentage is not constant over the entire time course. The 
percentage generally increases with time and is highest at the tail end of the 
plasma level curve9 An exception occurred with tablet U at the very early 
sampling times of 0.25 hr, when the percentage was high. The percentage is 
not, however, directly related to plasma prednisone levels9 
Table VI shows that the above percentage depends on the tablet ad- 
ministered, particularly during the absorption~tistribution phase (0.25- 
3 hr). When the "standard" tablet (U) was compared to tablets N, R, and 
D, there were differences between these average percentages at seven of the 
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Table VI. Results of O r d i n a r y  t Tests  (t) and  Pa i red  t Tests  (t*) for Average Percentages Shown 
in Tab le  V 
Table t  U vs. 
Time (hr) Table t  N Table t  R Table t  D 
0.25 t = 3.95 t = 4.59 - -  
p < 0.001 p < 0.001 
0.5 t* = 7.71 t* = 3.90 t = 4.18 
p < 0.001 0.01 > p > 0.001 0.01 > p > 0.001 
1 t* = 3.16 t* = 4.09 t = 2.27 
0.01 > p > 0.001 0.01 > p > 0.001 0.05 > p > 0.02 
2 t* = 2.14 t* = 2.50 t* = 0.0765 
N.S. (p > 0.05) 0,05 > p > 0.02 N.S. (p > 0.25) 
3 t* = 2.45 t* = 2.21 t* = 1.73 
0.05 > p > 0.02 0.05 > p > 0.02 N.S. (p > 0.10) 
4 t* = 0.47 t* = 0.41 t* = 0.021 
N.S. (p > 0.25) N.S. (p > 0.25) N.S. (p > 0.25) 
6 t* = 2.73 t* = 2.10 t* = 1,17 
0.05 > p > 0.01 N.S.(0.10 > p > 0.05) N.S. (p  > 0.20) 
8 t* = 2.89 t* = 1.47 t* = 1.90 
0.05 > p > 0.01 N.S.(p  > 0.10) N.S.(0.10 > p > 0.05) 
12 t = 3.63 t* = 2.43 t* = 4.78 
0.005 > p ,> 0.001 0.05 > p > 0.01 p < 0.001 
and at four of the nine sampling times for tablet D, since the 0.25 hr must 
be included in the count for the last tablet for the reason explained in the 
footnote to Table V. 
It is interesting that the average percentages taken over all sampling 
times and tablets are relatively constant from subject to subject (Table VII). 
Table VII. Average Percentage a by Subject  
Subject  M e a n  C.V. (%) 
1 28.6 32.7 
2 27.3 34.0 
3 26.4 35.2 
4 33.4 33.9 
5 27.5 34.4 
6 27.1 33.2 
7 27.9 41.5 
8 29.1 51.2 
9 32.7 38.3 
10 29.6 27.7 
11 28.6 30.8 
12 32.4 31.6 
~Percentage = 100 x p l a s m a  concen t ra t ion  of 
p redn i sone / (p l a sma  concen t r a t ion  of predni -  
sone  + p l a sma  concen t r a t ion  of prednisolone) .  
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Half-Lives of Prednisone and Prednisolone in Study 2 
There were no significant differences among average treatment half- 
lives of either prednisone or prednisolone (Table III and IV). The overall 
average half-lives of prednisone and prednisolone were 3.59 and 2.93 hr, 
respectively. The half-lives measured in the individual subjects are shown in 
Table VIII according to treatment. 
A paired t test was used to show that the difference between average 
half-lives of prednisone and prednisolone was significant (p < 0.001). That 
is, the plasma half-lives of prednisone and prednisolone are different, with 
that of prednisone being longer than that of prednisolone. 
Plasma Levels of Prednisolone in Study 3 
Tables IX and X summarize the results of the third prednisone study. 
In this study as in Study 1 (6) only prednisolone plasma concentrations were 
measured. ANOVA of plasma concentrations indicated highly significant 
tablet differences among average plasma concentrations of prednisolone at 
all sampling times through 2 hr. Tablet S was selected as the "standard" 
in this study, and when it was compared to the other tablets using Dunnett's 
multiple comparison procedure only the comparison of tablet S vs. tablet B 
gave consistently significant differences between average plasma concentra- 
tions through 2 hr. Similarly, the average peak plasma concentration follow- 
ing tablet S was significantly different from the average for tablet B. 
Tablet L was significantly different from tablet S only when the average 
plasma concentration of prednisolone at 0.25 hr was compared. Tablet Mc 
was significantly different from tablet S when the average plasma concentra- 
tions of prednisolone at 2 hr and the average areas (0-12 hr) following these 
tablets were compared. No other difference among tablet averages was 
significant for the parameters tested. 
The results of these two studies support the conclusion of a previous 
prednisone bioavailability study (6): that of the commercial prednisone 
tablets which have been studied in this laboratory (now numbering ten) 
these tablets differ mainly in the rate of appearance of prednisolone in the 
plasma but most probably not in the amount of prednisolone which reaches 
the circulation. That the results document that differences in in vivo rates of 
appearance of prednisolone in man correlate with in vitro rates of dissolu- 
tion of prednisone will be demonstrated in a subsequent report. 
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